(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Inovio Pharmaceuticals, Cardiff Oncology, and Capricor Therapeutics.

The three biggest losers today are China Liberal Education Holdings Limited, Marathon, and Viking Therapeutics.

Winners today

1. Inovio Pharmaceuticals (INO) – 18.27%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals jumping 18.27% to $12.04 on Monday, after two consecutive sessions in a row of gains. NASDAQ dropped 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-6.09.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -79.55%.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 1820320 which is 283.78% above its average volume of 474311.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 52.1% and 42.9%, respectively.

Moving Average

Inovio Pharmaceuticals’s worth is way above its 50-day moving average of $7.64 and way higher than its 200-day moving average of $5.96.

More news about Inovio Pharmaceuticals.

2. Cardiff Oncology (CRDF) – 17.95%

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

NASDAQ ended the session with Cardiff Oncology rising 17.95% to $4.14 on Monday, following the last session’s upward trend. NASDAQ dropped 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Cardiff Oncology has a trailing twelve months EPS of $-0.93.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.07%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 21.9%, now sitting on 488k for the twelve trailing months.

Moving Average

Cardiff Oncology’s value is way above its 50-day moving average of $1.88 and way higher than its 200-day moving average of $1.57.

More news about Cardiff Oncology.

3. Capricor Therapeutics (CAPR) – 16.87%

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

NASDAQ ended the session with Capricor Therapeutics jumping 16.87% to $5.89 on Monday while NASDAQ fell 0.41% to $16,019.27.

Earnings Per Share

As for profitability, Capricor Therapeutics has a trailing twelve months EPS of $-1.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -445.82%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Capricor Therapeutics’s stock is considered to be oversold (<=20).

Sales Growth

Capricor Therapeutics’s sales growth is 234.9% for the present quarter and 0.1% for the next.

More news about Capricor Therapeutics.

4. EHang Holdings Limited (EH) – 14.72%

EHang Holdings Limited operates as an autonomous aerial vehicle (AAV) technology platform company in the People's Republic of China, North America, East Asia, Europe, West Asia, and internationally. It designs, develops, manufactures, sells, and operates AAVs, as well as their supporting systems and infrastructure for a range of industries and applications, including passenger transportation, logistics, smart city management, and aerial media solutions. EHang Holdings Limited has a strategic partnership with Shenzhen Expressway Operation Development Company Limited. The company was incorporated in 2014 and is headquartered in Guangzhou, the People's Republic of China.

NASDAQ ended the session with EHang Holdings Limited rising 14.72% to $13.09 on Monday while NASDAQ dropped 0.41% to $16,019.27.

Earnings Per Share

As for profitability, EHang Holdings Limited has a trailing twelve months EPS of $-0.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -132.61%.

Yearly Top and Bottom Value

EHang Holdings Limited’s stock is valued at $13.09 at 17:32 EST, way below its 52-week high of $25.78 and way higher than its 52-week low of $8.63.

More news about EHang Holdings Limited.

5. CleanSpark (CLSK) – 13.58%

CleanSpark, Inc. engages in bitcoin mining operations. It develops sustainable infrastructure for Bitcoin, a tool for financial independence and inclusion. The company was formerly known as Stratean Inc. and changed its name to CleanSpark, Inc. in November 2016. CleanSpark, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with CleanSpark jumping 13.58% to $20.24 on Monday, after three sequential sessions in a row of gains. NASDAQ dropped 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, CleanSpark has a trailing twelve months EPS of $-0.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.24%.

Moving Average

CleanSpark’s value is way higher than its 50-day moving average of $12.33 and way higher than its 200-day moving average of $7.09.

Volume

Today’s last reported volume for CleanSpark is 58042600 which is 71.78% above its average volume of 33787500.

More news about CleanSpark.

6. Bilibili (BILI) – 13.3%

Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, live broadcasting, and story mode. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Bilibili jumping 13.3% to $12.61 on Monday, following the last session’s upward trend. NASDAQ slid 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Bilibili has a trailing twelve months EPS of $-1.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.46%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Bilibili’s EBITDA is -3.74.

Volatility

Bilibili’s last week, last month’s, and last quarter’s current intraday variation average was 0.09%, 0.27%, and 3.06%.

Bilibili’s highest amplitude of average volatility was 3.11% (last week), 2.69% (last month), and 3.06% (last quarter).

Moving Average

Bilibili’s worth is way above its 50-day moving average of $10.24 and below its 200-day moving average of $13.53.

More news about Bilibili.

7. Corbus Pharmaceuticals Holdings (CRBP) – 11.43%

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

NASDAQ ended the session with Corbus Pharmaceuticals Holdings jumping 11.43% to $44.93 on Monday while NASDAQ slid 0.41% to $16,019.27.

Earnings Per Share

As for profitability, Corbus Pharmaceuticals Holdings has a trailing twelve months EPS of $-11.12.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -224.63%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 9.6% and 64.2%, respectively.

Volume

Today’s last reported volume for Corbus Pharmaceuticals Holdings is 773146 which is 13.35% below its average volume of 892328.

More news about Corbus Pharmaceuticals Holdings.

8. BlackBerry (BB) – 10.69%

BlackBerry Limited provides intelligent security software and services to enterprises and governments worldwide. The company operates through three segments: Cybersecurity, IoT, and Licensing and Other. The company offers CylancePROTECT, an endpoint protection platform and mobile threat defense solution; CylanceOPTICS, an endpoint detection and response solution; CylanceGUARD, a managed detection and response solution; CylanceGATEWAY, an AI-empowered zero-trust network access solution; CylancePERSONA, a user and entity behavior analytics solution; BlackBerry unified endpoint management, a central software component for secure communications platform; BlackBerry Dynamics, a development platform and secure container for mobile applications; and BlackBerry Workspaces solutions. It also provides BlackBerry SecuSUITE, a multi-OS voice and text messaging solution; BlackBerry AtHoc and BlackBerry Alert, which are secure and networked critical event management solutions; BlackBerry QNX that offers real-time operating systems, hypervisors, middleware, development tools, and professional services; BlackBerry Certicom, a cryptography and key management product; BlackBerry Radar, an asset monitoring solution; and BlackBerry IVY, an intelligent vehicle data platform. In addition, the company is involved in the patent licensing and legacy service access fees business. The company has a partnership with Stellar Cyber Inc. to deliver Open XDR for comprehensive threat detection and response. The company was formerly known as Research In Motion Limited and changed its name to BlackBerry Limited in July 2013. BlackBerry Limited was incorporated in 1984 and is headquartered in Waterloo, Canada.

NYSE ended the session with BlackBerry rising 10.69% to $3.06 on Monday, after five sequential sessions in a row of gains. NYSE slid 0.14% to $17,863.69, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, BlackBerry has a trailing twelve months EPS of $-0.99.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.59%.

More news about BlackBerry.

9. Evofem Biosciences (EVFM) – 10.55%

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.

NASDAQ ended the session with Evofem Biosciences jumping 10.55% to $0.02 on Monday, following the last session’s downward trend. NASDAQ fell 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Evofem Biosciences has a trailing twelve months EPS of $38.97.

Moving Average

Evofem Biosciences’s worth is way below its 50-day moving average of $0.03 and way under its 200-day moving average of $0.27.

Revenue Growth

Year-on-year quarterly revenue growth declined by 19.8%, now sitting on 13.56M for the twelve trailing months.

Yearly Top and Bottom Value

Evofem Biosciences’s stock is valued at $0.02 at 17:32 EST, way under its 52-week high of $5.00 and way above its 52-week low of $0.01.

Volume

Today’s last reported volume for Evofem Biosciences is 1820330 which is 104.23% above its average volume of 891273.

More news about Evofem Biosciences.

10. Avid Bioservices (CDMO) – 10%

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

NASDAQ ended the session with Avid Bioservices rising 10% to $6.71 on Monday, following the last session’s upward trend. NASDAQ slid 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Avid Bioservices has a trailing twelve months EPS of $-0.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.28%.

More news about Avid Bioservices.

Losers Today

1. China Liberal Education Holdings Limited (CLEU) – -16.44%

China Liberal Education Holdings Limited provides educational services and products under the China Liberal brand name in the People's Republic of China. The company offers Sino-foreign jointly managed academic programs, including undergraduate and postgraduate education; and diploma and non-degree higher education, and senior secondary education programs in the areas of languages, liberal arts, and businesses. It also provides overseas study consulting and technological consulting services for Chinese universities to enhance their campus information and data management system, as well as to optimize their teaching, operating, and management environment. The company's consulting services include campus intranet solution buildout, school management software customization, smart devices, installation and testing, and school management data collection and analysis. In addition, it sells textbooks and other course materials, and AI-space products to students enrolled under the Sino-foreign Jointly Managed Academic Programs, as well as offers job readiness training to graduating students. China Liberal Education Holdings Limited was founded in 2011 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with China Liberal Education Holdings Limited dropping 16.44% to $1.22 on Monday, after five sequential sessions in a row of losses. NASDAQ fell 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, China Liberal Education Holdings Limited has a trailing twelve months EPS of $-2.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.78%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 229.6%, now sitting on 17.89M for the twelve trailing months.

More news about China Liberal Education Holdings Limited.

2. Marathon (MARA) – -12.1%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the bitcoin ecosystem in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon falling 12.1% to $20.64 on Monday while NASDAQ fell 0.41% to $16,019.27.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $1.06.

PE Ratio

Marathon has a trailing twelve months price to earnings ratio of 19.47. Meaning, the purchaser of the share is investing $19.47 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.09%.

Sales Growth

Marathon’s sales growth is 234.9% for the present quarter and 72% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Marathon’s EBITDA is 16.14.

Yearly Top and Bottom Value

Marathon’s stock is valued at $20.64 at 17:32 EST, way below its 52-week high of $34.09 and way higher than its 52-week low of $5.35.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.01%, a positive 0.12%, and a positive 7.11%.

Marathon’s highest amplitude of average volatility was 6.69% (last week), 7.97% (last month), and 7.11% (last quarter).

More news about Marathon.

3. Viking Therapeutics (VKTX) – -11.62%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics sliding 11.62% to $63.44 on Monday, after four successive sessions in a row of losses. NASDAQ fell 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.79%.

More news about Viking Therapeutics.

4. Canaan (CAN) – -10.9%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan dropping 10.9% to $1.39 on Monday while NASDAQ slid 0.41% to $16,019.27.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-2.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.6%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Canaan’s EBITDA is -2.22.

Revenue Growth

Year-on-year quarterly revenue growth declined by 11.2%, now sitting on 211.48M for the twelve trailing months.

Moving Average

Canaan’s value is way below its 50-day moving average of $1.84 and way under its 200-day moving average of $2.04.

Sales Growth

Canaan’s sales growth is negative 27% for the present quarter and negative 14.5% for the next.

More news about Canaan.

5. Creative Realities (CREX) – -10%

Creative Realities, Inc., together with its subsidiaries, provides digital marketing technology and solutions in the United States and internationally. It offers digital merchandising systems and omni-channel customer engagement systems; interactive digital shopping assistants; advisors and kiosks; and other interactive marketing technologies, such as mobile, social media, point-of-sale transactions, beaconing, and Web-based media that enables its customers to engage with their consumers. The company also provides system hardware; professional and implementation services; software design and development; and software licensing, deployment, and maintenance and support services, as well as media management and distribution software platforms and networks; device and product management; and customized software service layers, systems, experiences, workflows, and integrated solutions. The company sells its solutions to the automotive, apparel and accessories, banking, baby/children, beauty, CPG, department stores, digital out-of-home, electronics, fashion, fitness, foodservice/quick service restaurant, financial services, gaming, luxury, mass merchants, mobile operators, and pharmacy retail industries. Creative Realities, Inc. is headquartered in Louisville, Kentucky.

NASDAQ ended the session with Creative Realities sliding 10% to $3.42 on Monday while NASDAQ slid 0.41% to $16,019.27.

Earnings Per Share

As for profitability, Creative Realities has a trailing twelve months EPS of $-0.22.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.15%.

Yearly Top and Bottom Value

Creative Realities’s stock is valued at $3.42 at 17:32 EST, way below its 52-week high of $4.35 and way above its 52-week low of $1.22.

Moving Average

Creative Realities’s value is above its 50-day moving average of $3.16 and way above its 200-day moving average of $2.53.

More news about Creative Realities.

6. Plug Power (PLUG) – -9%

Plug Power Inc. develops hydrogen and fuel cell product solutions in North America, Europe, Asia, and internationally. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenKey, an integrated turn-key solution for transitioning to fuel cell power. It also provides electrolyzers, a hydrogen generator for clean hydrogen production; liquefaction systems that provides liquid hydrogen to customers; cryogenic equipment for the distribution of liquified hydrogen, oxygen, argon, nitrogen and other cryogenic gases, including trailers and mobile storage equipment; and liquid hydrogen, an alternative fuel to fossil-based energy. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was incorporated in 1997 and is headquartered in Latham, New York.

NASDAQ ended the session with Plug Power falling 9% to $3.66 on Monday, after two sequential sessions in a row of gains. NASDAQ slid 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Plug Power has a trailing twelve months EPS of $-2.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.34%.

Volatility

Plug Power’s last week, last month’s, and last quarter’s current intraday variation average was 2.16%, 0.17%, and 6.39%.

Plug Power’s highest amplitude of average volatility was 5.73% (last week), 5.79% (last month), and 6.39% (last quarter).

Sales Growth

Plug Power’s sales growth is negative 11.3% for the ongoing quarter and negative 12.3% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Plug Power’s stock is considered to be oversold (<=20).

More news about Plug Power.

7. Gevo (GEVO) – -8.54%

Gevo, Inc. operates as a renewable fuels company. It operates through three segments: Gevo, Agri-Energy, and Renewable Natural Gas. The company offers renewable gasoline and diesel, isooctane, isobutanol, sustainable aviation fuel, renewable natural gas, isobutylene, ethanol, and animal feed and protein. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was incorporated in 2005 and is headquartered in Englewood, Colorado.

NASDAQ ended the session with Gevo dropping 8.54% to $0.72 on Monday, after two successive sessions in a row of losses. NASDAQ dropped 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Gevo has a trailing twelve months EPS of $-0.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.39%.

More news about Gevo.

8. Groupon (GRPN) – -7.48%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon sliding 7.48% to $17.56 on Monday, after four consecutive sessions in a row of gains. NASDAQ fell 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-4.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -567.07%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Groupon’s stock is considered to be oversold (<=20).

Volatility

Groupon’s last week, last month’s, and last quarter’s current intraday variation average was 1.42%, 1.03%, and 3.01%.

Groupon’s highest amplitude of average volatility was 2.10% (last week), 2.37% (last month), and 3.01% (last quarter).

Moving Average

Groupon’s worth is way higher than its 50-day moving average of $15.12 and way higher than its 200-day moving average of $11.15.

More news about Groupon.

9. Corvus Pharmaceuticals (CRVS) – -7.02%

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

NASDAQ ended the session with Corvus Pharmaceuticals falling 7.02% to $2.12 on Monday, following the last session’s downward trend. NASDAQ slid 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Corvus Pharmaceuticals has a trailing twelve months EPS of $-0.64.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -55.41%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Corvus Pharmaceuticals’s EBITDA is -6.6.

Moving Average

Corvus Pharmaceuticals’s worth is below its 50-day moving average of $2.13 and higher than its 200-day moving average of $2.01.

More news about Corvus Pharmaceuticals.

10. Crexendo (CXDO) – -6.84%

Crexendo, Inc. provides cloud communication platform and services, video collaboration, and managed IT services for businesses in the United States, Canada, and internationally. It operates through two segments, Cloud Telecommunications and Software Solutions. The Cloud Telecommunications segment provides telecommunications services that transmit calls using Internet protocol (IP) or cloud technology, which converts voice signals into digital data packets for transmission over the Internet or cloud; and broadband Internet services. This segment is also involved in the sale and lease of cloud telecommunications equipment. In addition, it offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over high-speed internet connection through various devices and user interfaces, such as desktop phones and/or mobile, and desktop applications under the Crexendo brand name. The Software Solutions segment provides suite of unified communications, video conferencing, collaboration, and contact center solutions. This segment also offers SNAPsolution, a IP-based platform; and SNAPaccel, a software-as-a-service based software, as well as provides subscription maintenance and support, and professional services, including consulting, technical support, resident engineer, design, and installation services. The company was formerly known as iMergent, Inc. and changed its name to Crexendo, Inc. in May 2011. Crexendo, Inc. was incorporated in 1995 and is based in Tempe, Arizona.

NASDAQ ended the session with Crexendo dropping 6.84% to $5.99 on Monday, following the last session’s downward trend. NASDAQ fell 0.41% to $16,019.27, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Crexendo has a trailing twelve months EPS of $-0.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.84%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Mar 30, 2023, the estimated forward annual dividend rate is 0.02 and the estimated forward annual dividend yield is 0.33%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 150% and 25%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Crexendo’s EBITDA is 2.83.

Volume

Today’s last reported volume for Crexendo is 555557 which is 93.37% above its average volume of 287300.

More news about Crexendo.

Stay up to date with our winners and losers daily report